Trial Profile

A Phase 1, Double-Blind, Parallel Group Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Quadruple Therapy (Bismuth, Clarithromycin, and Amoxicillin) With Vonoprazan Versus Quadruple Therapy With Esomeprazole

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 01 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vonoprazan (Primary) ; Amoxicillin; Clarithromycin; Esomeprazole; Tripotassium dicitratobismuthate
Indications Helicobacter pylori infections
Focus Pharmacokinetics
Sponsors Takeda

11 Oct 2022 Primary endpoint has been met (AUC: Area Under the Plasma Concentration-time Curve From Time 0 to Time tau () Over the Dosing Interval for Bismuth) , according to Results presented at the 30th United European Gastroenterology Week
11 Oct 2022 Primary endpoint has been met (Cmax: Maximum Observed Plasma Concentration for Bismuth) , according to Results presented at the 30th United European Gastroenterology Week
11 Oct 2022 Results presented at the 30th United European Gastroenterology Week

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com